AbbVie Inc (ABBV)vsEnliven Therapeutics Inc. (ELVN)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ELVN
Enliven Therapeutics Inc.
$41.23
-2.76%
HEALTHCARE · Cap: $2.58B
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ELVN
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for ELVN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Safe zone — low bankruptcy risk
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ELVN
The strongest argument for ELVN centers on Altman Z-Score.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ELVN
The primary concerns for ELVN are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ELVN carries more volatility with a beta of 0.49 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 25/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Enliven Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Enliven Therapeutics Inc. (Ticker: ELVN) is a pioneering biotechnology firm dedicated to revolutionizing cancer therapy and tackling other critical illnesses through its proprietary therapeutic platforms. The company boasts a robust pipeline of innovative drug candidates developed via advanced biopharmaceutical technologies aimed at improving patient outcomes and enhancing quality of life. With a strong emphasis on scientific innovation and a commitment to addressing significant unmet medical needs in oncology, Enliven is well-positioned to drive shareholder value and make meaningful contributions to the healthcare ecosystem.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?